Literature DB >> 12480182

Synaptotagmin I and IV are differentially regulated in the brain by the recreational drug 3,4-methylenedioxymethamphetamine (MDMA).

Weiping Peng1, Arumugam Premkumar, Rainald Mossner, Mitsunori Fukuda, K Peter Lesch, Rabi Simantov.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy) is a widely abused drug. In brains of mice exposed to MDMA, we recently detected altered expression of several cDNAs and genes by using the differential display polymerase chain reaction (PCR) method. Expression of one such cDNA, which exhibited 98% sequence homology with the synaptic vesicle protein synaptotagmin IV, decreased 2 h after MDMA treatment. Herein, the effect of MDMA on expression of both synaptotagmin I and IV was studied in detail, since the two proteins are functionally interrelated. PCR analyses (semi-quantitative and real-time) confirmed that upon treatment with MDMA, expression of synaptotagmin IV decreased both in the midbrain and frontal cortex of mice. Decreases in the protein levels of synaptotagmin IV were confirmed by Western immunoblotting with anti-synaptotagmin IV antibodies. In contrast, the same exposure to MDMA increased expression of synaptotagmin I in the midbrain, a region rich in serotonergic neurons, but not in the frontal cortex. This differential expression was confirmed at the protein level with anti-synaptotagmin I antibodies. MDMA did not induce down- or up-regulation of synaptotagmin IV and I, respectively, in serotonin transporter knockout mice (-/-) that are not sensitive to MDMA. Therefore, psychoactive drugs, such as MDMA, appear to modulate expression of synaptic vesicle proteins, and possibly vesicle trafficking, in the brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480182     DOI: 10.1016/s0169-328x(02)00518-1

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  5 in total

1.  Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD.

Authors:  B S da Silva; R B Cupertino; D L Rovaris; J B Schuch; D B Kappel; D Müller; C E Bandeira; M M Victor; R G Karam; N R Mota; L A Rohde; V Contini; E H Grevet; C H D Bau
Journal:  Mol Psychiatry       Date:  2017-05-02       Impact factor: 15.992

2.  Loss of synaptotagmin IV results in a reduction in synaptic vesicles and a distortion of the Golgi structure in cultured hippocampal neurons.

Authors:  C P Arthur; C Dean; M Pagratis; E R Chapman; M H B Stowell
Journal:  Neuroscience       Date:  2010-02-04       Impact factor: 3.590

3.  Ketamine Inhibits ATP-Evoked Exocytotic Release of Brain-Derived Neurotrophic Factor from Vesicles in Cultured Rat Astrocytes.

Authors:  Matjaž Stenovec; Eva Lasič; Mićo Božić; Saša Trkov Bobnar; Randy F Stout; Vladimir Grubišić; Vladimir Parpura; Robert Zorec
Journal:  Mol Neurobiol       Date:  2015-12-12       Impact factor: 5.590

4.  Release mode of large and small dense-core vesicles specified by different synaptotagmin isoforms in PC12 cells.

Authors:  Zhen Zhang; Yao Wu; Zhao Wang; F Mark Dunning; Jonathan Rehfuss; Deepshika Ramanan; Edwin R Chapman; Meyer B Jackson
Journal:  Mol Biol Cell       Date:  2011-05-05       Impact factor: 4.138

5.  Synaptotagmin-IV modulates synaptic function and long-term potentiation by regulating BDNF release.

Authors:  Camin Dean; Huisheng Liu; F Mark Dunning; Payne Y Chang; Meyer B Jackson; Edwin R Chapman
Journal:  Nat Neurosci       Date:  2009-05-17       Impact factor: 24.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.